首页> 外国专利> ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS

ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS

机译:人工基因STBL_RBD_TRM_SC2,编码由SARS-COV-2冠状病毒糖蛋白S受体结合域序列,跨膜区,P2A-肽和糖蛋白GSV肽,蛋白膜,SV蛋白,重组蛋白组成的双原发结构,由SARS-COV-2冠状病毒糖蛋白组成。和重组菌株的水泡病毒RVSV-STBL_RBD_TRM_SC2,用于制备抗SARS-COV-2冠状病毒的疫苗

摘要

FIELD: biotechnology.;SUBSTANCE: described is an artificial gene Stbl_RBD_TrM_SC2 used to create a vaccine against SARS-CoV-2 coronavirus, coding an artificial protein-immunogen, which is a bicistronic structure consisting of receptor-binding domain (RBD) sequences of SARS-CoV-2 coronavirus glycoprotein S, heterological signal peptide haemagglutinin (HA) of influenza A virus, transmembrane region, linker, P2A-peptide for splitting polyprotein during translation and glycoprotein G with mutation M(1)P(1), preventing alternative translation initiation, presented in SEQ ID NO:1 with length of 2463 bp. Described is a recombinant plasmid pStem-rVSV-Stbl_RBD_TrM_SC2, having molecular weight of 8.92⋅106 dalton, size 14417 bp, presented in Fig. 2. Disclosed is a strain of rVSV-Stbl_RBD_TrM_SC2 of recombinant virus of vesicular stomatitis obtained using a recombinant plasmid pStem-rVSV-Stbl_RBD_TrM_SC2, which provides independent synthesis of coronavirus antigen (receptor-binding domain of glycoprotein S of SARS-CoV-2 with transmembrane region) and G protein of vesicular stomatitis virus, used to create a vaccine against SARS-CoV-2 coronavirus and deposited in the State collection of viral infection causative agents, rickettsioses of State Research Center of Virology and Biotechnology VECTOR of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, No. V-983.;EFFECT: technical result is improved folding of the transmembrane immunogen, higher stability of the target transgene and immunogenic / antigenic properties of the declared recombinant virus.;3 cl, 4 dwg, 2 tbl, 5 ex
机译:领域:描述了一种人工基因Stbl_RBD_TrM_SC2,用于创建抗SARS-CoV-2冠状病毒的疫苗,编码一种人工蛋白免疫原,其是由SARS受体结合域(RBD)序列组成的双顺反子结构-CoV-2冠状病毒糖蛋白S,甲型流感病毒的异源信号肽血凝素(HA),跨膜区,接头,在翻译过程中分裂多蛋白的P2A肽和糖蛋白G(突变M(1)> P(1)),从而防止了替代SEQ ID NO:1所示的翻译起始,长度为2463bp。描述了一种重组质粒pStem-rVSV-Stbl_RBD_TrM_SC2,分子量为8.92⋅10 6 道尔顿,大小为14417bp,如图2所示。公开了一种重组病毒的rVSV-Stbl_RBD_TrM_SC2菌株。使用重组质粒pStem-rVSV-Stbl_RBD_TrM_SC2获得的水泡性口腔炎,该质粒可独立合成冠状病毒抗原(具有跨膜区的SARS-CoV-2糖蛋白S的糖蛋白S的受体结合域)和水泡性口腔炎病毒的G蛋白,针对SARS-CoV-2冠状病毒的疫苗,并存放在病毒感染病原体的国家馆藏中,国家病毒与生物技术国家研究中心的立克次体,联邦消费者权益保护与人类健康监督服务部VECTOR,编号V-983。效果:技术成果是改善了跨膜免疫原的折叠性,提高了目标转基因的稳定性以及所宣称的重组病毒的免疫原性/抗原性。3 cl,4 dwg,2 tbl,5 ex

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号